Table 2.

U.S. FDA-Approved Fluorinated Drugs for Infectious Diseases (2018–2022).

Drug	Approval Date	Composition	Company	Indication	Drug Mechanism
Biktarvy	2/7/2018	Bictegravir Sodium, Emtricitabine and Tenofovir alafenamide fumarate	Gilead Sciences	HIV infection	Integrase strand transfer inhibitor, two HIV nucleoside analog reverse transcriptase inhibitors
Akynzeo	4/19/2018	Netupitant and palonosetron	Eisai	Nausea	NK1 receptor antagonist and 5-HT3 receptor antagonist
TPOXX	7/13/2018	Tecovirimat	SigaTechnologies	Smallpox	Orthopoxvirus VP37 envelope wrapping protein inhibitor
Krintafel	7/20/2018	Tafenoquine	GlaxoSmithKline	Malaria relapse prevention	8-aminoquinoline antiparasitic
Xerava	8/27/2018	Eravacycline	Tetraphase Pharmaceuticals	Complicated intraabdominal infections	Antibiotic, binds 30S ribosomal subunit to block protein synthesis
Pifeltro	8/30/2018	Doravirine	Merck & Co.	HIV-1 infection	Antiviral, reverse transcriptase inhibitor
Xofluza	10/24/2018	Baloxavir marboxil	Shionogi, Genentech	Influenza	Antiviral inhibitor of influenza polymerase acidic protein
Pretomanid	8/14/2019	Pretomanid	Global Alliance for TB Drug Development	Treatmentresistant tuberculosis	Nitroimidazooxazine antimycobacterial
Cabenuva	1/21/2021	Cabotegravir and Rilpivirine	ViiV Healthcare	HIV	HIV-1 antiretrovirals
Voquezna	5/3/2022	Vonoprazan, Amoxicillin, and Carithromycin	Phathom Pharmaceuticals	Helicobacter Pylori Infection	Proton pump inhibitor and antimicrobials
Vivjoa	4/26/2022	Oteseconazole	Mycovia Pharmaceuticals	Recurrent vulvovaginal candidiasis	14α-Demethylase inhibitor
Sunlenca	12/22/2022	Lenacapavir	Gilead Sciences	HIV infections in adults that cannot be successfully treated with other available treatments	HIV-1 antiretroviral agent

The source of the data is the U.S. FDA Web site [51].